AVP and metabolic syndrome: Canivell and colleagues have shown that age and apparent 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity modulate the association of copeptin with insulin resistance but not metabolic syndrome nor type 2 diabetes mellitus [122].